Supplementary Figure 6 from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma Through PI3K and IGF1R Inhibition

Concomitant inhibition of PI3Kβ, IGF1R and MAPK signaling are leading to full long-term pathway blockade. A) +B) Effects of treatment with the indicated inhibitors as single-agents or in combination on WM-266-4 (A) or RVH-421 (B) were evaluated by immunoblotting using phospho-specific or total target protein antibodies. PI3Kβi=rac-KIN-193, PI3Kαi=BYL719, IGF1Ri (A)=AEW541, IGF1Ri (B)=Figitumumab-like antibody, MEKi=MEK162